Antithrombotic therapy in patients undergoing TAVI: An overview of Dutch hospitals

Netherlands Heart Journal

Volumn 22, Issue 2, 2014, Pages 64-69

  Nijenhuis, V J ^a   Stella, P R ^b   Baan, J ^c   Brueren, B R G ^d   de Jaegere, P P ^e   den Heijer, P ^f   Hofma, S H ^g   Kievit, P ^h   Slagboom, T ⁱ   van den Heuvel, A F M ^j   van der Kley, F ^k   van Garsse, L ^l   van Houwelingen, K G ^m   van't Hof, A W J ⁿ   ten Berg, J M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f AMPHIA HOSPITAL   (Netherlands)

^g Medical Centre   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m MEDISCH SPECTRUM TWENTE   (Netherlands)

ⁿ ISALA HOSPITAL   (Netherlands)

more..

Author keywords

Aspirin; Bleeding; Clopidogrel; Dual antiplatelet therapy (DAPT); Thrombosis; Transcatheter aorticvalve implantation (TAVI)

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; HEPARIN; THIENOPYRIDINE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DECISION MAKING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NETHERLANDS; SINGLE DRUG DOSE; STRUCTURED INTERVIEW; THROMBOCYTOPENIA; TRANSCATHETER AORTIC VALVE IMPLANTATION;

EID: 84896642538     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0496-6     Document Type: Article

References (27)

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-607.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98.
3. Généreux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted metaanalysis of 3,519 patients from 16 studies. J Am Coll Cardiol. 2012;59(25):2317-26.
4. Khatri PJ, Webb JG, Rodes-Cabau J, et al. Adverse effects associated with transcatheter aortic valve implantation a meta-analysis of contemporary studies. Ann Intern Med. 2013;158(1):35-46.
5. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-96.
6. Holmes DR, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012;59(13):1200-54.
7. Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol. 2012;28(5):520-8.
8. THV-Group. Dutch Guidelines for Transcatheter Heart Valve Intervention [Internet]. 2012. Available from: https://www.nvvc.nl/ media/richtlijn/167/Guidelines%20THI%202012-DEF.pdf.
9. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart. 2012; 303095:1-6.
10. Halliday BP, Dworakowski R, Brickham B, et al. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol. 2012;109(5):724-8.
11. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686-95.
12. Van Mieghem NM, Nuis R-J, Tzikas A, et al. Prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2011;7(2):184-91.
13. Ussia GP, Barbanti M, Petronio AS, et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur Heart J. 2012;33(8):969-76.
14. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366(18):1705-15.
15. Moat NE, Ludman P, De Belder M, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011;58(20):2130-8.
16. Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur Heart J. 2011;32(2):198-204.
17. Nombela-Franco L, Webb JG, De Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126(25):3041-53.
18. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aorticvalve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696-704.
19. Nuis R-J, Van MieghemNM, Schultz CJ, et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol. 2012;109(11):1637-43.
20. Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation. 2006;114(15):1616-24.
21. Noble S, Asgar A, Cartier R, et al. Anatomo-pathological analysis after CoreValve Revalving system implantation. EuroIntervention. 2009;5(1):78-85.
22. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-40.
23. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16): 1433-41.
24. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28(6):726-32.
25. LambertsM, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013 Jun 6.
26. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Feb;12: 1107-15.
27. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60(15):1438-54. Elsevier Inc.